Back | Next |
home / stock / lexx / lexx message board
Subject | By | Source | When |
---|---|---|---|
Codfather, consider VOTING NO against repricing options as | Tech99989 | investorshub | 04/29/2023 8:01:00 PM |
NetworkNewsWire: Lexaria Bioscience Corp.s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indic | NetworkNewsWire | investorshangout | 04/28/2023 8:01:34 PM |
Few more shares I will make top ten investers | codfather | investorshub | 04/28/2023 3:50:47 PM |
MomentumIts gaining | PotsandPans420 | investorshub | 04/28/2023 2:22:26 PM |
$LEXX Lets go go go go... Up up and away we go. | all4weed | investorshub | 04/27/2023 3:45:34 AM |
short squeeze | codfather | investorshub | 04/26/2023 7:15:30 PM |
MomentumIts gaining | adam69 | investorshub | 04/26/2023 1:08:01 PM |
$LEXX Lets go go go go... Up up and away we go. | Shawking | investorshub | 04/25/2023 10:06:02 AM |
bears are running | all4weed | investorshub | 04/25/2023 4:00:25 AM |
Time for a bounce? | harlem111 | investorshub | 04/24/2023 10:09:12 PM |
Price gaining last trade up | PotsandPans420 | investorshub | 04/24/2023 6:32:15 PM |
Lexaria Awards CRO Contract for Upcoming U.S. Phase | Shawking | investorshub | 04/24/2023 2:51:00 PM |
Ted Ohashi-Let's Toke Business | Shawking | investorshub | 04/24/2023 10:05:50 AM |
Price gaining | harlem111 | investorshub | 04/24/2023 8:46:02 AM |
what does this mean? | harlem111 | investorshub | 04/23/2023 9:43:21 AM |
The gaining | Shawking | investorshub | 04/22/2023 7:48:36 PM |
Here's annual letter which contains the list of | Shawking | investorshub | 04/21/2023 6:03:32 PM |
$LEXX great news | Shawking | investorshub | 04/21/2023 11:38:58 AM |
Price now | PotsandPans420 | investorshub | 04/20/2023 10:46:43 PM |
NetworkNewsWire: NetworkNewsBreaks Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with | NetworkNewsWire | investorshangout | 04/20/2023 7:33:22 PM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
3.3%Change Percent:
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Website:
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...